Johns Hopkins, Bayer HealthCare Collaborate to Develop Ophthalmic Therapies

Johns Hopkins, Bayer HealthCare Collaborate to Develop Ophthalmic Therapies

Attendees at the Johns Hopkins – Bayer HealthCare collaboration kick-off event

The Johns Hopkins University and Bayer HealthCare entered into a five-year collaboration agreement on June 15 to jointly develop new ophthalmic therapies targeting retinal diseases.

The goal of the strategic research alliance is to accelerate the translation of innovative approaches from the laboratory to the clinic, ultimately offering patients new treatment options for several retinal diseases.

Under the agreement, researchers at the Wilmer Eye Institute at Johns Hopkins and Bayer HealthCare will jointly conduct research activities evaluating new targets and disease mechanisms, drug delivery technologies, and biomarkers for back-of-the-eye diseases with high unmet medical need.

Both parties will contribute personnel and infrastructure to address important scientific questions. Bayer HealthCare will have an option for the exclusive use of the collaboration results.

“There is a critical need for new therapies that treat a variety of serious diseases of the eye,” says Peter McDonnell, director of the Wilmer Eye Institute and professor of ophthalmology at the Johns Hopkins University School of Medicine. “Additional research will allow us the opportunity to make significant advances in this area.”

The collaboration aims to discover and develop innovative drugs for the treatment of serious back-of-the-eye diseases that affect many people worldwide, such as:

  • Age-related macular degeneration
  • Diabetic macular edema
  • Geographic atrophy
  • Stargardt’s disease
  • Retinal vein occlusion

“The Wilmer Eye Institute’s deep understanding of eye disease biology and patient care and Bayer’s expertise in drug discovery and development in ophthalmology complement each other perfectly,” says Professor Andreas Busch, head of global drug discovery at Bayer HealthCare and a member of Bayer HealthCare’s executive committee. “We are pleased to partner with this renowned institute, which is among the leading scientific and clinical institutions in ophthalmology worldwide.”

Work on projects that are a part of this exciting collaboration will begin later this summer.
Click here to view highlights from the Johns Hopkins-Bayer HealthCare collaboration kick-off event.
Back to newsletter